NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019Deborah K. Armstrong, Anita M. Engh, Jonathan S. Berek et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 332
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparibMargaret Whicker, Elena Ratner|BMC Cancer|2016Cited by 34
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to OlaparibCai M. Roberts, Elena Ratner|Cancers|2023Cited by 6
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to OlaparibCai M. Roberts, Elena Ratner|Preprints.org|2023Cited by 5
Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancerWafa Khadraoui, Gulden Menderes, Christina Tierney et al.|International Journal of Gynecology & Obstetrics|2020Cited by 2